FDA to review AcelRx's pain candidate

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) said FDA accepted for review an NDA for Dsuvia sufentanil sublingual tablet to treat moderate to severe acute pain in a medically supervised setting. Its PDUFA date is Oct. 12.

AcelRx said FDA plans to hold an advisory committee meeting to review the NDA, but a date has not yet been determined...